Benefits of Legal Funding for Actemra Lawsuits

Ava Lawson | September 18th, 2017

Lawsuits against Big Pharma can be extensive, lengthy and draining. When pharmaceutical products end up causing more harm than good, the results are often life-altering. Such are the allegations surrounding the relatively new arthritis drug, Actemra, which has been linked to a host of complications including heart failure, stroke, gastrointestinal perforation, pancreatis, lung disease and even death.  Actemra — prescribed to patients who failed to respond to traditional therapies for rheumatoid arthritis — earns big money for drug manufacturer Roche (Genentech), and generated sales of nearly $1.8 billion last year. Plaintiffs contend that Roche failed to warn patients and the medical community about Actemra’s dangerous side effects.

According to an investigative report by STAT, subsidiary Genentech promoted Actemra as a safer alternative to competing medications like Enbrel, Humira and Remicad, misleading patients and their doctors about risks.

Actemra lawsuits allege failure to warn

Actemra litigation is still in the early stages, but as more injury actions are filed, there is a good possibility that lawsuits will be consolidated under multidistrict litigation (MDL) before a federal judge. While a useful procedural step in large mass torts involving similar allegations against a common defendant, this also portends a much longer waiting period for plaintiffs.

Whether you or someone you love suffered a heart attack or stroke while taking Actemra, getting legal funding can help maintain your economic stability and quality of life until litigation resolves. Here at LawStreet Capital, we believe that money difficulties shouldn’t determine the fate of your case. We help level the playing field when taking on deep-pocketed defendants like drug manufacturers, which are only interested in protecting their bottom line.

A lawsuit cash advance provides plaintiffs the funds needed to not only hire the best legal representation, but also cover household expenses and bills as they wait for a settlement or trial verdict.  If you have already filed an Actemra lawsuit, or are considering bringing a claim but worried about money, there are several advantages to legal funding.

Wait for a fair settlement with legal funding

Proving liability in drug injury claims is a complex and tedious process that can last for months or even years. Lawsuit funding offers a financial cushion during the litigation process, allowing plaintiffs some breathing room and security.

Legal funding isn’t a loan like you’d get at the bank. It is an advance based on the strengths and projected value of your case. With funding in hand, plaintiffs don’t have to accept an unfair settlement amount because they can’t afford to pay rent or meet daily expenses.

Pre settlement loans aren’t the answer for everyone, but they do offer numerous advantages, especially when compared to credit card advances or third-party loans.

  • Approval is fast, most claims are approved in 24 hours
  • No credit checks or collateral needed
  • Free application with no hidden fees
  • Money can be used for anything, without restriction
  • All legal funding is provided on a non-recourse basis
  • Competitive interest rates
  • No repayment unless you win money in your case

It’s important to understand that LawStreet litigation funding is 100 percent risk-free. If you win or settle your lawsuit, our fees are taken from your monetary award. But if you lose your case, you owe absolutely nothing!

Get the most out of your Actemra lawsuit by partnering with LawStreet Capital today. Start your free legal funding application by calling 866-FUND-662.   

Additional Resources on Actemra Litigation:

  1. Stat News, Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients https://www.statnews.com/2017/06/05/actemra-rheumatoid-arthritis-fda/
  2. FDA, FDA approves first drug to specifically treat giant cell arteritis https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559791.htm